EGFR and non-small cell lung carcinoma: Animal models for pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) were exploited as surrogate for KRASG12D patients' response to Erlotinib and Bevacizumab, therapeutics targeting epidermal growth factor (EGFR) and vascular endothelial growth factor (VEGF), respectively.